Evidence map›Paper›PMID 37662589›Full record

ArticleJVS-vascular science2023

Biological mechanisms of infection resistance in tissue engineered blood vessels compared to synthetic expanded polytetrafluoroethylene grafts.

Juan Wang, Shelby K F Blalock, Garyn S Levitan, Heather L Prichard, Laura E Niklason, Robert D Kirkton

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in JVS-vascular science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02644941 (An Assessment of Humacyte's Human Acellular Vessel in Patients Needing Renal Replacement Therapy), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02644941 phase3completednot on this map

An Assessment of Humacyte's Human Acellular Vessel in Patients Needing Renal Replacement Therapy: A Comparison With ePTFE Grafts as Conduits for Hemodialysis (HUMANITY)

TypeinterventionalSponsorHumacyte, Inc.Ran2016 to 2023Enrolled355ConditionsRenal Failure, End Stage Renal Disease, Hemodialysis, Vascular AccessArmsHuman Acellular Vessel (HAV), ePTFE graft
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Bioengineered human blood vessels to treat hospital-acquired vascular complications.Journal of vascular surgery cases and innovative techniques · 2025
    Article
  5. Artificial blood vessels-clinical development of TEVG.Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs · 2025
    Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Juan WangHumacyte, Inc., Durham, NC.
Shelby K F BlalockHumacyte, Inc., Durham, NC.
Garyn S LevitanHumacyte, Inc., Durham, NC.
Heather L PrichardHumacyte, Inc., Durham, NC.
Laura E NiklasonHumacyte, Inc., Durham, NC.
Robert D KirktonHumacyte, Inc., Durham, NC.
Humacyte (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Synthetic expanded polytetrafluoroethylene (ePTFE) grafts are known to be susceptible to bacterial infection. Results from preclinical and clinical studies of bioengineered human acellular vessels (HAVs) have shown relatively low rates of infection. This study evaluates the interactions of human neutrophils and bacteria with ePTFE and HAV vascular conduits to determine whether there is a correlation between neutrophil-conduit interactions and observed differences of their infectivity in vivo. Methods: A phase III comparative clinical study between investigational HAVs (n = 177) and commercial ePTFE grafts (n = 178) used for hemodialysis access (ClinicalTrials.gov Identifier: NCT02644941) was evaluated for conduit infection rates followed by histological analyses of HAV and ePTFE tissue explants. The clinical histopathology of HAV and ePTFE conduits reported to be infected was compared with immunohistochemistry of explanted materials from a preclinical model of bacterial contamination. Mechanistic in vitro studies were then conducted using isolated human neutrophils seeded directly onto HAV and ePTFE materials to analyze neutrophil viability, morphology, and function. Results: Clinical trial results showed that the HAV had a significantly lower (0.93%; Conclusions: The HAV material seems to demonstrate a resistance to bacterial infection. This infection resistance is likely due to the HAV's native-like material composition, which may be more biocompatible with host neutrophils than synthetic vascular graft material.

Indexed as

Bacterial infectionExpanded polytetrafluoroethylene (ePTFE)NeutrophilsSynthetic vascular graftsTissue-engineered blood vessels

Identifiers

PMID37662589
PMCPMC10474492
OpenAlexW4384157243

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.